



Dkt. 58463/JPW/EMW

Gen 1643

#4
Dkt
8/28/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Harold J. Wanebo and Shashikant Mehta
Serial No. : 09/287,884 Examiner: Not Yet Known
Filed : April 7, 1999 Group Art Unit: 1643
For **RECEIVED** COMBINATIONS OF CERAMIDE AND CHEMOTHERAPEUTIC
AUG 23 1999 AGENTS FOR INDUCING CELL DEATH AND USES
THEREOF IN TREATING CANCER

TECH CENTER 1600/2900

1185 Avenue of the Americas
New York, New York 10036
August 13, 1999

Honorable Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

RECEIVED
AUG 20 1999
TC 1700 MAIL ROOM

Applicants submit herewith an Information Disclosure Statement under 37 C.F.R. §1.56.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following disclosures:

1. Baselga, J. et al. (1997) HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncol. Mar 11 (3 suppl 2), 43-48. (Exhibit 1).
2. Jayadev, S. et al. (1995) Role for ceramide in cell cycle arrest. J. Biol. Chem. 270(5):2047-2052. (Exhibit 2).
3. Mathias, S., et al. (1998) Signal transduction of stress via ceramide. Biochem. J. 335:465-480. (Exhibit 3).

Applicants: Harold J. Wanebo and Shashikant Mehta
Serial No.: 09/287,884
Filed: April 7, 1999
Page 2

4. Perez, E.A. et al. (1998) Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines. Cancer Chemother. Pharmacol. 41(6): 448-452, 1998. (Exhibit 4).
5. Shirahama, T. et al. (1997) In vitro and in vivo induction of apoptosis by sphingosine and N, N-dimethylsphingosine in human epidermoid carcinoma KB-3-1 and its multidrug-resistant cells. Clin. Cancer Res. 3:257-264. (Exhibit 5).

Each of the above-listed references is listed again on the accompanying PTO Form 1449 (Exhibit A), and copies of references 1-5 are attached hereto as Exhibits 1-5, respectively.

Applicants request that the Examiner review the references and make them of record in the subject application.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Applicants: Harold J. Wanebo and Shashikant Mehta
Serial No.: 09/287,884
Filed: April 7, 1999
Page 3

If a telephone conference would be of assistance in advancing the prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone at the number provide below.


Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231.

 John P. White
Reg. No. 28,678

8/13/99
Date